- Disease Flare-ups in Patients with Systemic Rheumatic Disease Following COVID-19 Vaccination
- People with Gout and COVID-19
- COVID-19 outcomes in individuals with systemic lupus erythematosus (SLE)
- Model to Predict the Risk of COVID-19 Acute Respiratory Distress Syndrome in Patients With Rheumatic Diseases
- Psoriatic Arthritis, Axial Spondyloarthritis, or Psoriasis & COVID
- Regional Environmental and Socioeconomic Risk Factors in COVID-19-Related Death for People with Rheumatic Disease
- Idiopathic Inflammatory Myopathy and COVID
- Long COVID in people with SARDs
- Pregnancy Outcomes: Researchers Recommend COVID-19 Vaccination for Women Living with a Rheumatic Disease
- Patients with rheumatic and musculoskeletal diseases had higher rates of SARS-CoV-2 infection and increased odds of death
- Vaccine perceptions among people with rheumatic disease
- COVID-19 Pandemic Impact on Rheumatic Patients’ Health, Healthcare Utilization, and Behaviors
- COVID-19 When Pregnant and Living with a Rheumatic Disease
- Survey of COVID-19 vaccination experiences in patients with systemic rheumatic disease
- Tumor Necrosis Factor Inhibitors and COVID-19 related hospitalization and death in patients suffering from immune-mediated inflammatory disease
- The risk of severe COVID-19 outcomes for people with vasculitis or polymyalgia rheumatica
- Plain Language Summary for a study that shows the associations between b/tsDMARDs, taken by rheumatoid arthritis (RA) patients, and the severity of their COVID-19 illness outcomes
- Plain Language Summary of Characteristics associated with Covid-19 in patients with Rheumatic Disease in Latin America: data from the Covid-19 Global Rheumatology Alliance physician-reported registry (added 15 July 2021)
- Plain Language Summary of Medications Impacting Response to COVID-19 Vaccines (added 23 April 2021)
- Plain Language Summary of Factors Associated with COVID-19 Related Death for People with Rheumatic Disease (added 5 February 2021)
- Plain Language Visual Abstract of our #ACR20 Abstract 6: Race/ethnicity Is Associated with Poor Health Outcomes Amongst Rheumatic Disease Patients Diagnosed with COVID-19 in the US
- Plain Language Summary of COVID-19 Global Rheumatology Alliance’s First Provider-Reported Data Analysis
- Original Article: Gianfrancesco M, Hyrich KL, Al-Adely S, et al. Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry. Annals of the Rheumatic Diseases. [Epub ahead of print 29 May 2020]. doi: 10.1136/annrheumdis-2020-217871
- Efficacy of Antirheumatic Disease Therapies in Patients with COVID-19: A Systematic Review and Meta-analysis of the Current Evidence
- Epidemiology and outcomes of novel coronavirus 2019 in patients with immune-mediated inflammatory diseases
- Original Article: Gianfrancesco M, Yazdany J, Robinson PC. Epidemiology and outcomes of novel coronavirus 2019 in patients with immune-mediated inflammatory diseases [published online ahead of print, 2020 Jul 15]. Curr Opin Rheumatol. 2020;10.1097/BOR.0000000000000725. doi: 10.1097/BOR.0000000000000725
- Plain Language Summary of COVID-19 and Hydroxychloroquine
- Plain Language Summary of Race/Ethnicity association with COVID-19 Outcomes in Rheumatic Disease
- Original Article: Milena A. Gianfrancesco et al. on behalf of the COVID‐19 Global Rheumatology Alliance. [published online ahead of print, 03 November 2020].Race/ethnicity association with COVID‐19 outcomes in rheumatic disease: Data from the COVID‐19 Global Rheumatology Alliance Physician Registry. Arthritis & Rheumatology (2020) doi: https://doi.org/10.1002/art.41567